Biotech firm raises $20 million, sees progress on Covid-19 vaccine

Oragenics Inc. (NYSE: OGEN), a Tampa-based biotech firm, has raised $20 million from the sale of common stock and will use some of the funding to boost its research into a Covid-19 vaccine. The company’s vaccine, known as Terra CoV-2 and produced from a spike protein licensed from the National Institutes of Health, has gone through one round of clinical trials, to date, and a second phase is in the works. According to a Feb. 2 news release, the vaccine has been shown to produce protective immunity to the coronavirus in mice.

“We are in scale-up phase right now,” Oragenics President and CEO Dr. Alan Joslyn said in an interview with the Catalyst. “Our goal is to have an immediate intense response, which will hopefully lead to the development of a single-dose vaccine.”

Preservation, workforce initiatives combine in planned affordable housing development in Campbell Park

Panel discussion delves into rise of B Corps

Localtopia in review: Good news and bad apples

St. Petersburg’s downtown and waterfront were jammed Saturday, as Localtopia took over Williams Park and surrounding streets, and the St. Pete Pier was so popular that the on-site parking lots were filled by noon, a guard stationed at the entrance to turn vehicles away.

Ep 49 – St. Petersburg Conference on World Affairs

Create

The Shuffle

Alex Lewis

AmeriLife

WE WANT TO HEAR FROM YOU!

Subscribe    Unsubscribe    Contact    Partner